Tag: Dr John Reed

dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.

Connect with Us

36,531FansLike
94FollowersFollow
342FollowersFollow
2,523FollowersFollow
5,339FollowersFollow
37SubscribersSubscribe